Kancera
- Biotech or pharma, therapeutic R&D
Kancera is a clinical stage biotech that is developing a new class of small molecule drug candidates targeting the fractalkine axis. The fractalkine axis controls certain specific immune cells known to be disease promoting in a number of inflammatory conditions, autoimmune diseases and cancers. Kancera’s new class of drugs includes the drug candidates KAND567 (lead program in phase II) and KAND145 (2nd generation with completed phase I).
The lead program aims to prevent hyper-inflammation in connection with percutaneous coronary intervention in acute myocardial infarction (AMI).
Kancera reported positive outcome of pre-IND meeting with the FDA on June 5 concerning the continued clinical development of KAND567 in AMI.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}